JUVÉDERM® VOLUX™ XC Gains FDA-Approval for Jawline Improvement

JUVÉDERM® VOLUX™ XC is the first and only hyaluronic acid (HA) filler to receive U.S. FDA approval for improving jawline definition. For adults over the age of 21 with moderate to severe jawline definition loss, this cutting-edge injectable represents the most significant leap in innovation for the JUVÉDERM® HA portfolio. VOLUX™ XC complements the existing product line to increase structure, cohesivity, and lift capacity, creating an improved jawline that appears more defined in real life and on camera. 

As people age, many factors, such as genetics and soft tissue loss, can contribute to how the lower face changes. This can cause reduced definition around the jawline area that may impact and change the shape of the face and lead to the appearance of jowls.

Compared to other hyaluronic acid fillers, VOLUX™ XC is much denser, making it perfect for restoring volume to the shape and structure of the lower face. This creates a smooth contour along the jawline and reduces the appearance of jowls. Results include significant definition between the jaw and neck and more voluminous cheeks for a more sculpted, youthful appearance.

Statistics and side effects

Some statistics coming out of the pivotal JUVÉDERM® VOLUX™ XC clinical study include:

  • 81.5% of participants were satisfied with how sculpted (well-defined) their jawline looked at six months
  • 70.5% of participants were satisfied with how smooth their lower face looked (i.e., no jowls or folds of fatty skin) at six months
  • 73.1% of participants at six months were satisfied with how nice their lower faces looked
  • At six months post-treatment, 89.7% of treatment group participants were willing to recommend VOLUX™ XC to a friend, with the majority continuing to recommend treatment at 12 months
  • Participants reported satisfaction using the Satisfaction with Lower Face, and Jawline module of the FACE-Q questionnaire
  • Most treatment group participants reported satisfaction with the appearance of their lower face and jawline through twelve months following treatment

Commonly reported side effects in the clinical study included:

  • Tenderness
  • Lumps and bumps
  • Pain
  • Swelling
  • Firmness
  • Bruising
  • Redness
  • Itching
  • Discoloration at the injection sites

VOLUX™ XC side effects are consistent with HA filler injections and were usually mild to moderate in severity. Most of these side effects resolve on their own within two weeks.



We have been fully operational since May of 2020. With patience and with care, we all are returning to normalcy. Our office continues to use safety protocols, and we are eager to see you.


For patients who desire a virtual consultation, this option is available.
Our virtual web consultations can be done right in the comfort of your own home. All you need is a secure Internet connection and a computer, tablet, or smartphone.
If you would like to have a VIRTUAL CONSULTATION or have any questions, please give us a call at (425) 827-7878 or contact us via our website to set up your virtual consultation today.


Updated May 2022
We have been fully operational since May of 2020. This includes skincare and our non-invasive center (ENIC).
We know that so much of this pandemic caused an inconvenience for you, but we are delighted to see a return to normalcy. 
We will continue to be vigilant in our approach to Covid 19. For over two decades, we have considered safety as our most important prerogative — and there has never been a more important time to put that to use.
Here are some things we’re doing to ensure you are protected and that we maintain this facility as a Non-Covid Care (NCC) zone:

Patient Flow and Clinical Office Space

We now have a well-tested protocol of texting patients for control of flow for consultations.
We are assigning everyone to hourly wipe-downs of high-use areas with approved sanitizing wipes.
We are asking that no one wait in the waiting area.
We are coming up with protocols for room wipe-downs after each patient visit.
Every staff member will always wear a mask while in the office.
Every staff member will sanitize or wash hands after every interaction.
Implementation of virtual pre-ops, nursing visits, and questions.

Operating Room Experience

Similar precautions and questionnaires will be provided to establish Covid-19 Clear Status.
All staff will always wear a mask. All staff will always wear gloves.
Hand washing will be done for any patient interaction.
Specific wipe-down of our operating room, recovery, and pre-op areas will be performed.
We will minimize accompanying caretakers to only one. Those caretakers will be treated just like the patients.
Anesthesia Experience
Every anesthesia staff will wear goggles and other protective equipment during intubation.
Our anesthesiologists have been fully trained and are implementing all precautions for prevention of Covid-19 spread.
All circuits will be changed between each patient.
Full wipe-down of surfaces and floors will be performed.
We will implement a time-out protocol to confirm the Covid-19 Clear Status of every patient.

As you can see, we are taking this very seriously. We fully understand that this will cause some inconvenience in the short term, but realize that it is for the best.
Although Covid-19 has been a serious issue, we are seeing a resumption of normalcy. We continue to monitor this situation on a real-time basis, and we will not sit back until we know that we have done everything possible to avoid unnecessary exposure.
When you see us in action, you’ll realize that you have put your trust in the right practice.
Here are some links that might be useful:
State of Washington Department of Health
Centers for Disease Control and Prevention (CDC)
World Health Organization (WHO)
Please do not hesitate to contact us. We are always here to answer your questions!
Call us at (425) 827-7878
Email us at [email protected]

Contact us media

Terms & Conditions Privacy Policy Sitemap

© Egrari. All Rights Reserved.

Accessibility: If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact our Accessibility Manager at (425) 827-7878.
Contact Us